Prevention Of Psoriatic Arthritis Save
Dr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria.
Transcription
Hi, everyone. Peter Nashua reporting for RheumNow from EULA, Vienna 2024. One of the interesting elements that's discussed, the number of papers presented are thinking about ways of preventing psoriasis turning into psoriatic arthritis. Now this has been looked at with therapeutic implications. It's been looked at from a biomarker point of view, an imaging point of view, different ways of trying to define the highest risk patient and we can define them.
Bad family history, nail disease, a lot of skin rash, bad function requiring analgesia that is beyond the norm, those with arthralgia already and bad skin, scalp involvement, we can certainly define the patient is at the highest risk. And then it's a question of can we go into our PSO clinics, image them, biomarker them and see if we can define the patients who are going to either evolve into PSA and then the implication of what we're going to do about it. So a number of studies presented, one from a database of 200,000,000 people that had one million patients with psoriasis about a 100,000 already developed PSA and they looked at the use of various biologic agents in the PSO population and they're able to show when they compared 17 against TNF and when they compared 23 against TNF that those two were superior to TNFs in preventing the progression. The twenty three seem to be the best. The twelve twenty three and the twenty three inhibitors seem to be able to prevent the progression the best and it reduced that progression by about thirty seven percent.
So an area of increasing interest. They're looking for the biomarkers to help us decide who's progressing. They're looking at imaging data, particularly ultrasound, power Doppler, painted emphyseal sites, patients with arthralgia, see if we can prevent that progression and the use of active agents early on to try and prevent the progression. So we'll have to watch this space. Thanks for your attention.
Bad family history, nail disease, a lot of skin rash, bad function requiring analgesia that is beyond the norm, those with arthralgia already and bad skin, scalp involvement, we can certainly define the patient is at the highest risk. And then it's a question of can we go into our PSO clinics, image them, biomarker them and see if we can define the patients who are going to either evolve into PSA and then the implication of what we're going to do about it. So a number of studies presented, one from a database of 200,000,000 people that had one million patients with psoriasis about a 100,000 already developed PSA and they looked at the use of various biologic agents in the PSO population and they're able to show when they compared 17 against TNF and when they compared 23 against TNF that those two were superior to TNFs in preventing the progression. The twenty three seem to be the best. The twelve twenty three and the twenty three inhibitors seem to be able to prevent the progression the best and it reduced that progression by about thirty seven percent.
So an area of increasing interest. They're looking for the biomarkers to help us decide who's progressing. They're looking at imaging data, particularly ultrasound, power Doppler, painted emphyseal sites, patients with arthralgia, see if we can prevent that progression and the use of active agents early on to try and prevent the progression. So we'll have to watch this space. Thanks for your attention.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.